Lyra Therapeutics (LYRA) AI Stock Analysis

• Market Cap: $6.85M
• Dividend Yield: N/A
• Average Volume (3M): 75.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.58
• Revenue Growth: -59.21%
• EPS Growth: 68.97%
• Country: US
• Employees: 30
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -3.38
• Shares Outstanding: 1,774,882
• 10 Day Avg. Volume: 47,157
• 30 Day Avg. Volume: 75,484
• PEG Ratio: -0.53
• Price to Book (P/B): 57.96
• Price to Sales (P/S): 438.05
• P/FCF Ratio: -9.29
• Enterprise Value/Market Cap: 3.04
• Enterprise Value/Revenue: 34.77
• Enterprise Value/Gross Profit: 69.54
• Enterprise Value/Ebitda: -0.68
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -12.81
• Revenue Forecast (FY): $533.33K

• Rating: 45 Neutral
• Price Target: $4.00 ▲(3.63% Upside)

Lyra Therapeutics' overall stock score reflects significant financial challenges, including consistent losses and negative cash flows. Technical indicators show a bearish trend, and valuation metrics are poor due to a negative P/E ratio. These factors combine to create a high-risk investment profile.

Lyra Therapeutics Business Overview & Revenue Model

Company Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Lyra Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing deals that provide upfront payments, milestone payments based on development progress, and royalties on future product sales. Additionally, the company may seek funding through grants, public offerings, or private placements to support its research and development activities. As the company progresses its clinical trials and approaches potential commercialization of its products, it may also establish collaborations that enhance its revenue potential.

Lyra Therapeutics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Lyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 3.86 is above the 20-day moving average (MA) of 3.73, below the 50-day MA of 5.09, and below the 200-day MA of 7.17, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 43.79 is Neutral, neither overbought nor oversold. The STOCH value of 27.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.

Lyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
BOLT	49 Neutral	$10.46M	-0.24	-81.97%	―	-46.88%	34.83%
LYRA	45 Neutral	$6.85M	-0.16	-404.48%	―	-59.21%	68.97%
XTLB	39 Underperform	$7.64M	-7.00	―	―	―	65.45%
SLXN	34 Underperform	$8.16M	-0.10	-771.23%	―	―	91.47%
MBIO	31 Underperform	$7.81M	-0.86	-418.83%	―	―	98.58%
RNAZ	27 Underperform	$8.35M	-0.03	-1763.01%	―	―	96.75%

Lyra Therapeutics Corporate Events

Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the localized treatment of chronic rhinosinusitis (CRS) using its proprietary technology to deliver medicines directly to affected tissues. The company’s latest earnings report highlights ongoing challenges, including significant financial losses and restructuring efforts following the failure of a key clinical trial. During the third quarter of 2025, Lyra Therapeutics reported a net loss of $5.98 million, a decrease from the previous year’s $11.87 million loss for the same period. The company’s cash and cash equivalents decreased to $22.1 million from $40.6 million at the end of 2024, raising concerns about its ability to continue operations without additional funding. Lyra is actively seeking to sublease properties and reduce workforce costs to preserve cash. Looking forward, Lyra Therapeutics remains focused on addressing its financial challenges and exploring strategic options to sustain its operations, while continuing to evaluate the potential of its lead product candidate, LYR-210.

Lyra Therapeutics Posts Corporate Presentation on LYR-210

On September 4, 2025, Lyra Therapeutics announced the posting of a corporate presentation on their website, detailing their progress and future plans for LYR-210, a drug implant for chronic rhinosinusitis. The presentation highlighted the company’s recent achievements, including the successful completion of the ENLIGHTEN 2 Phase 3 trial, and outlined the regulatory path forward for LYR-210, which has shown promising results in both polyp and non-polyp CRS populations. Despite past challenges, such as the failure of the ENLIGHTEN 1 trial and financial difficulties, Lyra is focused on advancing LYR-210 towards approval and addressing the large unmet need in the CRS market.

The most recent analyst rating on (LYRA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Lyra Therapeutics Receives Nasdaq Deficiency Letter

On August 20, 2025, Lyra Therapeutics received a Deficiency Letter from Nasdaq indicating that the company’s stockholders’ equity, reported at $1.6 million as of June 30, 2025, did not meet the minimum requirement of $2.5 million for continued listing on the Nasdaq Capital Market. Although this has no immediate effect on the trading of its stock, Lyra has until October 4, 2025, to submit a plan to regain compliance. The company is exploring various strategies to meet Nasdaq’s requirements, but there is no guarantee of acceptance or successful compliance, which could lead to potential delisting.

The most recent analyst rating on (LYRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift

Lyra Therapeutics, Inc. faces significant business risks following the recent restart of manufacturing for LYR-210, primarily due to the transition from a contract manufacturing organization to an in-house facility. The company has yet to establish a commercial manufacturing capability, and ongoing reliance on outsourced services poses challenges, including potential lot failures and regulatory hurdles. Additionally, the reduction in experienced personnel after the May 2024 RIF could lead to production delays, impacting clinical and regulatory timelines. These factors, combined with potential trade disruptions, may hinder Lyra’s attractiveness to potential collaborators and affect its financial stability.

Lyra Therapeutics Reports Q2 2025 Financial Results

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS). The company recently reported its second-quarter 2025 financial results, highlighting significant progress in its clinical trials and financial strategy.